We are contrasting Celsion Corporation (NASDAQ:CLSN) and 22nd Century Group Inc. (NYSEAMERICAN:XXII) on their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation. They both are Biotechnology companies, competing one another.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|22nd Century Group Inc.||26.60M||9.47||11.43M||-0.07||0.00|
In table 1 we can see Celsion Corporation and 22nd Century Group Inc.’s top-line revenue, earnings per share (EPS) and valuation.
Table 2 hightlights the return on equity, return on assets and net margins of the two companies.
|Net Margins||Return on Equity||Return on Assets|
|22nd Century Group Inc.||-42.97%||0%||0%|
Risk and Volatility
A 2.18 beta means Celsion Corporation’s volatility is 118.00% more than Standard and Poor’s 500’s volatility. Competitively, 22nd Century Group Inc.’s 78.00% volatility makes it more volatile than Standard and Poor’s 500, because of the 1.78 beta.
The current Quick Ratio of Celsion Corporation is 4.6 while its Current Ratio is 4.6. Meanwhile, 22nd Century Group Inc. has a Current Ratio of 9.3 while its Quick Ratio is 8.7. 22nd Century Group Inc. is better positioned to pay off its short-term and long-term debts than Celsion Corporation.
Insider & Institutional Ownership
Roughly 9.8% of Celsion Corporation shares are owned by institutional investors while 26.5% of 22nd Century Group Inc. are owned by institutional investors. Insiders owned 0.1% of Celsion Corporation shares. Insiders Comparatively, owned 0.8% of 22nd Century Group Inc. shares.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|22nd Century Group Inc.||-2.86%||7.94%||-19.05%||-26.88%||-9.33%||-18.07%|
For the past year Celsion Corporation has 60.99% stronger performance while 22nd Century Group Inc. has -18.07% weaker performance.
22nd Century Group Inc. beats on 5 of the 9 factors Celsion Corporation.
Celsion Corporation, an oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The companyÂ’s lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. It is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
22nd Century Group, Inc., a plant biotechnology company, provides technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants to be decreased or increased through genetic engineering and plant breeding. It develops smoking cessation products and modified risk tobacco products for smokers who are unable or unwilling to quit smoking and who may be interested in cigarettes, which reduce exposure to nicotine or to certain tobacco smoke toxins and/or pose a lower health risk than conventional cigarettes. The companyÂ’s products include RED SUN and MAGIC regular and menthol cigarettes; and SPECTRUM government research cigarettes. It is also developing X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation; and modified risk cigarettes, such as BRAND A, which has approximately 95% less nicotine than conventional tobacco cigarettes, as well as BRAND B cigarettes that contain low amount of tar per milligram of nicotine. 22nd Century Group, Inc. has a scientific collaboration with the University of Virginia; and a strategic partnership with Anandia Laboratories, Inc. The company was founded in 1998 and is headquartered in Clarence, New York.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.